In response to a Freedom of Information Act request (FOIA) filed over three months ago, in August of 2021, the U.S. Food and Drug Administration (FDA) has asked a federal judge for 55 years to review its data before releasing it to the public in its entirety.
The data refers to the FDA’s decision to license BioNTech. Back in November of 2020, when considering Pfizer-BioNTech’s request for emergency use authorization (EUA) of its product, the FDA promised that:
“In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Committee … will meet to discuss the totality and safety and effectiveness data provided … The FDA understands there is tremendous public interest regarding vaccines for COVID-19. We remain committed to keeping the public informed about the evaluation of the data … so that once available, the public and the medical community can have trust and confidence in receiving the vaccine for our families and ourselves.”